114
Participants
Start Date
June 30, 2014
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Selinexor
"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
EGFR or HER2 Inhibitor
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
FGFR Inhibitor
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
C-KIT Inhibitor
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
Anti-androgen
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
NOTCH Inhibitor
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
MEK or PI3K Inhibitor
"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
Princess Margaret Cancer Centre, Toronto
University Health Network, Toronto
OTHER